Beta-microseminoprotein immunoreactivity as a new prognostic indicator of prostatic carcinoma
| Autor: | Yutaka Saito, Yuzo Minami, Ryouichi Tsuda, Hiroshi Kanetake, Ichiro Nakazono, Yasuo Yogi, Hideki Sakai, Hiroyuki Hyakutake, Yoshiaki Yushita |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
Male
Pathology medicine.medical_specialty medicine.drug_class Urology Monoclonal antibody complex mixtures Antigens Neoplasm Prostate parasitic diseases Carcinoma medicine Humans Stage (cooking) neoplasms Aged Proportional Hazards Models Aged 80 and over business.industry Biopsy Needle Seminal Plasma Proteins Prostatic Neoplasms Prostatic Secretory Proteins Proteins Beta-microseminoprotein Middle Aged Prognosis medicine.disease Immunohistochemistry Survival Analysis medicine.anatomical_structure Oncology Prostatic acid phosphatase Multivariate Analysis Prostate gland business |
| Zdroj: | The Prostate. 22:347-355 |
| ISSN: | 1097-0045 0270-4137 |
| DOI: | 10.1002/pros.2990220409 |
| Popis: | Human beta-microseminoprotein (beta-MSP), isolated from seminal plasma, is one of the proteins secreted by the prostate gland. To determine whether the beta-MSP immunoreactivity can be a prognostic indicator of prostatic carcinoma, the beta-MSP immunohistochemical distribution has been examined in needle biopsy specimens taken from 96 patients with prostatic carcinoma. Although no significant correlation was found between the beta-MSP immunoreactivity and the histological grade (Gleason score), patients with a positive beta-MSP expression had a significantly better prognosis than those with a negative beta-MSP expression (P = 0.01). Further, a multivariate analysis of six possible parameters (age, clinical stage, histological grade, serum prostatic acid phosphatase, beta-MSP immunoreactivity, and the type of initial treatment) has shown the difference in the beta-MSP immunoreactivity to be a significant, independent, prognostic indicator of prostatic carcinoma (P = 0.04). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text